Preclinical studies using cisplatin/carboplatin to restore the Enzalutamide sensitivity via degrading the androgen receptor splicing variant 7 (ARv7) to further suppress Enzalutamide resistant prostate cancer

The FDA-approved anti-androgen Enzalutamide (Enz) has been used successfully as the last line therapy to extend castration-resistant prostate cancer (CRPC) patients’ survival by an extra 4.8 months. However, CRPC patients eventually develop Enz-resistance that may involve the induction of the androg...

Descripción completa

Detalles Bibliográficos
Autores principales: Chou, Fu-Ju, Lin, ChangYi, Tian, Hao, Lin, WanYing, You, Bosen, Lu, Jieyang, Sahasrabudhe, Deepak, Huang, Chi-Ping, Yang, Vanessa, Yeh, Shuyuan, Niu, Yuanjie, Chang, Chawnshang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7606511/
https://www.ncbi.nlm.nih.gov/pubmed/33139720
http://dx.doi.org/10.1038/s41419-020-02970-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7606511/
https://www.ncbi.nlm.nih.gov/pubmed/33139720
http://dx.doi.org/10.1038/s41419-020-02970-4

Ejemplares similares